Lassa virus is endemic to the West Africa countries of Guinea, Sierra Leone, Liberia, Mali, Côte d’Ivoire, and Nigeria (1–3). The virus causes Lassa fever, a hemorrhagic disease with a case-fatality rate ≈30% in the current hospital setting in West Africa. So far, 4 lineages of Lassa virus are firmly established: lineages I, II, and III circulate in Nigeria, and lineage IV circulates in Guinea, Sierra Leone, Liberia, Mali, and Côte d’Ivoire (1–3). Recently, strains from Mali and Côte d’Ivoire were proposed to represent a separate lineage V (4). The newly discovered Lassa virus strain Kako from Hylomyscus pamfi rodents trapped in Nigeria is designated lineage VI for the purpose of this article (5).

Lassa virus has not been previously detected in humans or rodents in Togo; therefore, the virus was not considered endemic to this country. We describe a strain of Lassa virus representing a new lineage that was isolated from a cluster of human infections with an epidemiologic link to Togo (Technical Appendix) (6,7). The clinical courses of the 3 case-patients and medical and public health interventions are described elsewhere (8–10).

The Lassa virus infections in the index case-patient, secondary case-patient 1, and secondary case-patient 2 were confirmed by laboratory investigations at Bernhard Nocht Institute (Hamburg, Germany); Centers for Disease Control and Prevention (Atlanta, GA, USA); and Philipps University (Marburg, Germany), respectively. The viruses from all 3 patients were isolated in Vero E6 cell culture in the respective Biosafety Level 4 laboratories. Full-length virus sequences were generated directly from clinical specimens, from the isolates, or both using next-generation sequencing technology in combination with Sanger sequencing (sequences deposited into GenBank under accession nos. KU961971, KU961972, LT601601, LT601602, MF990886–MF990889) (Technical Appendix). The sequence from the index case-patient was submitted to GenBank on March 23, 2016, and immediately made publicly available to support the laboratory and public health response in Togo and the other affected countries.

The virtually identical viruses from the 3 patients confirmed the transmission chains suggested by the epidemiologic data. Only the virus from secondary case-patient 2 showed differences in coding regions—a deletion of 3 nt and a nucleotide exchange in the polymerase (L) gene—from the viruses in the other 2 case-patients. These differences were confirmed by sequencing the virus in the clinical specimens. Differences among the 3 strains in the highly structured intergenic regions might represent artifacts created by the difficulty in sequencing these regions.

Figure

Figure. Phylogeny of the Lassa virus strain from Togo, 2016. Phylogenetic trees were inferred using BEAST2 (https://www.beast2.org/) for full-length glycoprotein precursor (A), nucleoprotein (B), and polymerase (C) genes. The analysis included...

The phylogeny was inferred using BEAST2 (https://www.beast2.org/) with nucleotide sequences of full-length nucleoprotein (NP), glycoprotein precursor (GPC), and L and Z genes of the Togo strain in conjunction with representative sequences of Lassa virus and other Old World arenaviruses. The most stable reconstruction was obtained for the L gene with the Togo strain being placed in sister relationship with lineage II (all branches with posterior support values >0.97) (Figure). In the NP- and GPC-based phylogenies, the Togo strain clusters with lineages I and VI (Pinneo and Kako strains); however, the branching order is not well supported (posterior values 0.51–0.86) (Figure). The phylogeny based on the small Z gene further supports a relationship of the Togo strain with lineages I, II, and VI (Technical Appendix Figure 1). The ambiguous position of the Togo strain relative to lineages I, II, and VI is consistent with a recombination analysis showing that most of the L gene sequence is related to lineage II, and NP and GPC comprise sequence stretches mainly related to lineages I and VI (Technical Appendix Figure 2). This mosaic structure might be the result of recombination, reassortment, or both or might have evolved by chance.

The long branch (i.e., large phylogenetic distance) separating the Togo strain from known lineages suggests that it represents a new lineage. Because Lassa virus lineages were originally established on the basis of uncorrected sequence distances (1), we used the same method here. The frequency distribution of pairwise amino acid distances in GPC, NP, and L between the Togo strain and all other Lassa virus strains perfectly overlaps with the distribution of distances between Lassa virus lineages I, II, III, IV, and VI indicating that the Togo strain is a separate lineage (Technical Appendix Table 1). However, we noted that the distance between the proposed lineage V and lineage IV rather corresponds to intralineage distances, and therefore, we considered lineage V a subclade of lineage IV in our analysis (Technical Appendix Table 1). We propose that formal recognition of Lassa virus lineages should be decided by the International Committee on Taxonomy of Viruses.

In conclusion, sequencing Lassa virus from a cluster of imported infections, with the index case-patient originating from Togo, reveals a new lineage of Lassa virus in West Africa. It seems to be related to lineage II or lineages I/VI, which are all circulating in Nigeria.

Top